SEARCH

SEARCH BY CITATION

References

  • Alvers K. M., Beckmann J. S., Zheng G., Crooks P. A., Dwoskin L. P. and Bardo M. T. (2012) The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology 224, 255262.
  • Beckmann J. S., Denehy E. D., Zheng G., Crooks P. A., Dwoskin L. P. and Bardo M. T. (2012) The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology 220, 395403.
  • Damaj M. I., Patrick G. S., Creasy K. R. and Martin B. R. (1997) Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 282, 410419.
  • Darchen F., Scherman D. and Henry J. P. (1989) Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28, 113122.
  • Di Chiara G. and Imperato A. (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 85, 52745278.
  • Dwoskin L. P. and Crooks P. A. (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63, 8998.
  • Eisenhofer G., Kopin I. J. and Goldstein D. S. (2004) Leaky catecholamine stores: undue waste or a stress response coping mechanism? Ann. N. Y. Acad. Sci. 1018, 224230.
  • Fischer J. F. and Cho A. K. (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208, 203209.
  • Galli A., Blakely R. D. and DeFelice L. J. (1996) Norepinephrine transporters have channel modes of conduction. Proc. Natl Acad. Sci. USA 6, 86718676.
  • Gnegy M. E. (2003) The effect of phosphorylation on amphetamine-mediated outward transport. Eur. J. Pharmacol. 280, 8391.
  • Harrod S. B., Dwoskin L. P., Crooks P. A., Klebaur J. E. and Bardo M. T. (2001) Lobeline attenuates d-methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 280, 14321444.
  • Harrod S. B., Dwoskin L. P., Green T. A., Gehrke B. J. and Bardo M. T. (2003) Lobeline does not serve as a reinforcer in rats. Psychopharmacology 165, 397404.
  • Horton D. B., Siripurapu K. B., Zheng G., Crooks P. A. and Dwoskin L. P. (2011) Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J. Pharmacol. Exp. Ther. 339, 112.
  • Jones R. (2007) Double-blind, placebo-controlled, cross-over assessment of intravenous methamphetamine and sublingual lobeline interactions. NCT00439504. Clinical Trials.gov.
  • Kenakin T. P. (1993) Pharmacologic Analysis of Drug-Receptor Interaction, 2nd edn. Raven Press, New York.
  • Kenakin T. P. (2006) A Pharmacology Primer, Second Edition: Theory, Application, and Methods, 2nd edn. Academic Press, San Diego.
  • Kukkonen A., Perakyla M., Akerman K. E. O. and Nasman J. (2004) Muscarinic toxin 7 selectivity is dictated by extracellular receptor loops. J. Biol. Chem. 279, 5092350929.
  • Meyer A. C., Horton D. B., Neugebauer N. M., Wooters T. E., Nickell J. R., Dwoskin L. P. and Bardo M. T. (2011) Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration. Neuropharmacology 61, 849856.
  • Miller D. K., Crooks P. A., Zheng G., Grinevich V. P., Norrholm S. D. and Dwoskin L. P. (2004) Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J. Pharmacol. Exp. Ther. 310, 10351045.
  • Near J. A. (1986) [3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol. Pharmacol. 30, 252257.
  • Neugebauer N. M., Harrod S. B., Stairs D. J., Crooks P. A., Dwoskin L. P. and Bardo M. T. (2007) Lobelane decreases methamphetamine self-administration in rats. Eur. J. Pharmacol. 571, 3338.
  • Nickell J. R., Krishnamurthy S., Norrholm S., Deaciuc A. G., Siripurapu K. B., Zheng G., Crooks P. A. and Dwoskin L. P. (2010) Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J. Pharmacol. Exp. Ther. 332, 612621.
  • Nickell J. R., Zheng G., Deaciuc A. G., Crooks P. A. and Dwoskin L. P. (2011) Phenyl ring-substituted lobelane analogs: inhibition of [3H]dopamine uptake at the vesicular monoamine transporter-2. J. Pharmacol. Exp. Ther. 336, 724733.
  • Partilla J. S., Dempsey A. G., Nagpal A. S., Blough B. E., Baumann M. H. and Rothman R. B. (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther. 319, 237246.
  • Peter D., Liu Y., Brecha N. and Edwards R. H. (1995) The transport of neurotransmitters into synaptic vesicles. Prog. Brain Res. 105, 273281.
  • Pifl C., Drobny H., Reither H., Hornykiewicz O. and Singer E. A. (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47, 368373.
  • Pletscher A. (1977) Effect of neuroleptics and other drugs on monoamine uptake by membranes of adrenal chromaffin granules. Br. J. Pharmacol. 59, 419424.
  • Rudnick G. (1990) Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry 29, 603608.
  • Scherman D. and Henry J. P. (1984) Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 25, 113122.
  • Schuldiner S., Steiner-Mordoch S., Yelin R., Wall S. C. and Rudnick G. (1993) Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44, 12271231.
  • Sonders M. S. and Amara S. G. (1996) Channels in transporters. Curr. Opin. Neurobiol. 6, 294302.
  • Sonders M. S., Zhu S. J., Zahniser N. R., Kavanaugh M. P. and Amara S. G. (1997) Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 17, 960974.
  • Substance Abuse and Mental Health Services Administration. (2011) Results from the 2010 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-41, HHS Publication No. SMA 11-4856 Findings). Rockville, MD.
  • Sulzer D. and Rayport S. (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5, 797808.
  • Sulzer D., Sonders M. S., Poulsen N. W. and Galli A. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406433.
  • Teng L. H., Crooks P. A., Sonsalla P. K. and Dwoskin L. P. (1997) Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280, 14321444.
  • Teng L. H., Crooks P. A. and Dwoskin L. P. (1998) Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 71, 258265.
  • Tucek S. and Proska J. (1995) Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. 16, 205212.
  • Wise R. A. and Bozarth M. A. (1987) A psychomotor stimulant theory of addiction. Psychol. Rev. 94, 469492.
  • Wooters T. E., Smith A. M., Pivavarchyk M., Siripurapu K. B., McIntosh J. M., Zhang Z., Crooks P. A., Bardo M. T. and Dwoskin L. P. (2011) bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br. J. Pharmacol. 163, 346357.
  • Yelin R. and Schuldiner S. (2002) Vesicular neurotransmitter transporters pharmacology, biochemistry and molecular analysis, in Contemporary Neuroscience: Neurotransmitter Transporters: Structure, Function, and Regulation (Reith M. E. A., ed.), pp. 313354. Humana Press, Totowa, NJ.